Trial abstract · §3
LL37-PH1-2-VENOUSULCER — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in ulcer area after topical administration | A dose-dependent reduction in ulcer area at the low and intermediate doses only, with no effect at the highest dose | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for LL-37 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Local pain on intralesional administration | — | — | Reported |
| Local erythema | — | — | Reported |
| Cytotoxicity at high concentration | — | — | A property of the molecule rather than an idiosyncratic adverse effect; the highest dose in the clinical trial performed worse than intermediate doses |
| Haemolysis | — | — | Demonstrated in vitro at concentrations not greatly above antimicrobial concentrations |
Compound Evidence Institute · CEI-TR-0116/3 · https://compoundevidence.com/trials/ll37-ph1-2-venousulcer/results/ · retrieved 30 July 2026